ArticleCureus2026
Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with schizophrenia experience markedly reduced life expectancy, driven largely by cardiometabolic disease, and several of the most effective antipsychotics are also among those most likely to promote weight gain. Weight gain is among the adverse effects patients find least acceptable and one they frequently cite when they abandon treatment, which links metabolic harm directly to the non-adherence that precipitates relapse. Glucagon-like peptide-1 receptor agonists, now supported by randomized trials in schizophrenia-spectrum populations, reduce weight and metabolic burden without destabilizing psychiatric symptoms. In this editorial, we argue that their most consequential effect in serious mental illness may not be the weight they remove but the treatment they help patients keep taking: by neutralizing the adverse effect patients most resent, these agents may protect antipsychotic adherence itself. We call for trials that adopt adherence and discontinuation as endpoints and for psychiatry to reclaim ownership of cardiometabolic prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.